ClinicalTrials.gg
Enrolling by invitationNCT07442162prospectiveUpdated Mar 2, 2026

Effects of Melatonin on Excessive Crying in Neonates. A Randomized Controlled Clinical Trial.

A Phase 1/2 interventional study of use of multivitamin and one group of neonates with excessive crying receive melatonin orally n=83 in Crying, sponsored by Al-Hadba university. Enrolling by invitation at 1 site in Iraq. Open to participants aged 14 Days to 28 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Al-Hadba university · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
14 Days to 28 Days
Sex
All
01

Study summary

the goal of this clinical trial is to learn if melatonin could reduce the duration of excessive crying and infantile colic in neonates and if this drug can be an option to be used in treating such problem- infantile colic and crying which creates anxiety to the parents, and to assess the safety of using melatonin in neonates.

the author invited 165 mothers of 165 neonates having excessive crying more than 3 hours per day over 3 days per week, with ages ranged from 14-20 days with 4 categories of neonates according to the status of delivery: Cesarean section, Difficult labor, premature delivery, Small for gestational Age (IUGR) babies, as well as normal delivery neonates. these neonates will be randomly assigned into group Of melatonin 82 neonates, and 83 neonates will receive oral multivitamins as placebo that was made comparable to melatonin in taste and viscosity and color by the research pharmacy in Mosul, the dose of Melatonin will be 0.1mg/kg/12 hourly ,given daily up to 28 days of the start of administration of both melatonin and multivitamin. randomization is performed using opaque sealed envelopes which are sequentially numbered from 1-178 and allocation is concealed from mothers and the author. the clinic nurse will be the responsible for distribution of allocations. The mother will be instructed to record the daily duration of crying in minutes and report these values by telephone follow up throughout the study. The study design is a double-blinded randomized clinical trial. the whole study is to be conducted in a pediatric clinic prospectively. the group of neonates with melatonin will be compared with the group of neonates receiving multivitamins as placebo in the mean-crying times using t-tests

Read the detailed description

Introduction Excessive crying in early infancy is a common and distressing condition for parents and caregivers and represents a frequent cause of medical consultation during the neonatal period. Crying that persists for more than three hours per day, on more than three days per week, in an otherwise healthy infant is often described as excessive or inconsolable crying [1]. Although usually self limited, prolonged crying may negatively affect infant parent bonding, increase parental anxiety, and lead to inappropriate feeding practices or unnecessary medical investigations [2]. The etiology of excessive crying in infants is multifactorial and poorly understood, with proposed mechanisms including immaturity of the nervous system, gastrointestinal discomfort, and perinatal stresses [3].

Crying typically starts early in neonatal period, averaging two to three hours per day, and gradually declines by three to four months [4]. While most cases are benign, excessive crying has been associated with parental exhaustion, stress, and in rare cases, child abuse due to caregiver frustration [5]. Organic causes such as gastroesophageal reflux, cow's milk protein allergy, or urinary tract infection are identified in less than five percent of infants presenting with excessive crying [6]. The majority of cases are functional, often categorized under "infantile colic," which is defined by recurrent and prolonged episodes of crying without an identifiable medical cause [7]. Several hypotheses have been proposed to explain infantile colic and excessive crying, including gastrointestinal dysmotility, altered gut microbiota, food hypersensitivity, and psychosocial stressors [8]. Excessive crying in neonates can often be associated with perinatal stresses such as prematurity, difficult labor and intrauterine growth restriction IUGR [9]. Importantly, excessive crying is not only a medical issue but also a psychosocial one, as it can increase maternal depression risk, and strain family dynamics [10].

Management strategies for excessive crying range from parental reassurance and behavioral interventions to dietary modifications and pharmacological approaches. Probiotics such as Lactobacillus reuteri have shown promise in reducing crying duration by modulating gut microbiota [8]. Emerging evidence also suggests that melatonin may play a therapeutic role. Melatonin, a neurohormone secreted by the pineal gland, regulates circadian rhythms and has been implicated in gastrointestinal motility and antioxidant defense. Clinical trials have demonstrated that melatonin supplementation can improve sleep patterns and reduce infantile crying [11]. Its mechanisms include entrainment of circadian rhythms [12], modulation of gut motility [13], and stabilization of cortisol-melatonin balance [14]. Reviews emphasize melatonin's safety profile in neonates and its potential as a chronobiotic therapy [15].

Despite this interest in melatonin use in pediatric sleep disorders, evidence regarding its effect on excessive crying in early infancy still remains limited.

This study aims to evaluate the effect of oral melatonin drops on crying duration in neonates with excessive crying by assessing the daily mean-times in crying over a defined follow up period.

Methods Un-blinded randomized, controlled clinical study was conducted (according to CONSORT statement) in a private pediatric clinic in Mosul, Iraq, during the period from 15 January to June 2025, to evaluate the effect of melatonin on excessive crying in neonates. A total of 165 neonates aged 14-20 days (mean ±SD: 17 ±4 days) presenting with excessive crying were enrolled. Excessive crying in neonates was defined as crying lasting more than 3 hours per day on more than 3 days per week.

Infants were categorized according to potential perinatal risk factors: cesarean section (n = 26), difficult delivery (n = 63), intrauterine growth restriction/small for gestational age (IUGR/SGA) (n = 33), premature vaginal delivery (n = 21), and normal vaginal delivery (n = 12). Cesarean section was either emergency or elective. A delivery was considered difficult if labor was prolonged, perinatal minimal hypoxia or if episiotomy or obstetric maneuvers were required. Infants were categorized as small for gestational age SGA (intrauterine growth restriction, IUGR) when their birth weight was below the 10th percentile for gestational age.

Infants were recruited from neonates attending a private pediatric clinic in Mosul who presented with excessive crying, and detailed information was obtained through reports provided by their mothers. They were randomly assigned into two groups: Group A (melatonin, n = 83) and Group B (placebo, n = 82). Randomization was performed using opaque sealed envelopes, which were sequentially numbered from 1 to 178, and allocation was concealed from mothers, who were not informed whether their infant received melatonin or placebo.

Group A received melatonin drops at a dose of 0.1 mg/kg twice daily at night for 28 consecutive days, beginning on the first clinic visit [16]. Group B received placebo drops consisting of a multivitamin preparation.

Mothers documented the infants' crying duration in minutes on days 1,7,14, and 28, and reported these values via telephone. Throughout the study, mothers were instructed to report any unusual adverse effects potentially associated with melatonin use, including excessive sleepiness, vomiting, diarrhea, seizures, or skin rash.

Independent sample t-tests were performed to compare mean crying times between the two groups at days 1,7,14, and 28.

The melatonin preparation employed in this experiment was obtained from a reputable, pharmaceutical-grade brand, ensuring consistency, purity, and reliability of dosage.

The primary outcome was the mean crying times at days 1,7,14, and 28 Statistical analysis was performed using independent sample t tests to compare mean crying times between groups at each time point. A p value \< 0.05 was considered statistically significant. SPSS statistics version 30(2024) was used to analyze the data.

02

Conditions studied

  • Crying

Browse trials for

Keywords

  • melatonin, excessive crying
03

In context

Crying

39 studies on the registry are indexed under Crying; 8 are open to participants now.

This study's planned enrollment of 165 is above the median of 90 across 34 interventional studies indexed under Crying.

Browse Crying studies →

Lead sponsor

This is the only study on the registry with Al-Hadba university as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Days to 28 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: neonates with excessive crying, of more than 3 hours/day duration of crying, on more than 3 days per week, who are otherwise healthy without any apparent complications.

-

Exclusion Criteria: neonates with major birth complications, neurological disorders or medical pathology.

-

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
165 participants (estimated)

Study arms

  • Active comparator
    melatonin group

    group

    Drug: one group of neonates with excessive crying receive melatonin orally n=83

  • Placebo comparator
    placebo group

    group of the placebo 82 neonates with excessive crying but receiving placebo

    Drug: use of multivitamin

Interventions

  • Druguse of multivitamin

    melatonin used to calm the babies who suffer from infantile colic

  • Drugone group of neonates with excessive crying receive melatonin orally n=83

    two groups of neonates with excessive crying , group of melatonin oral drop , compared with the group of placebo (multivitamin oral drops) to find out the effect of melatonin on excessive crying status and comparing it with the effect of placebo on the excessive crying of the placebo(multivitamin drop orally),as to verify the effect of melatonin as an option to be used for infantile colic. the study is conducted in double-blinded. randomization.

06

What researchers measure

Primary outcomes

  1. effects of melatonin on the duration of crying in neonates

    the daily mean crying times between the group using melatonin and that of placebo (multivitamin drops) group

    Time frame: 28 days

  2. effect of melatonin on the mean time of daily duration of crying in minutes

    two groups of neonates group of using oral melatonin 83 neonates versus group of placebo multivitamin 82 neonates and comparison of mean time duration in minutes between the two groups

    Time frame: 28 days

07

Study locations

1 site
  • Al-hadba university
    Mosul, Nineveh Governorate 41, Iraq
08

References and documents

Publications

  • 1. Wessel MA, Cobb JC, Jackson EB, Harris GS, Detwiler AC (1954) Paroxysmal fussing in infancy, sometimes called colic. Pediatrics 14(5):421-435. 2. Barr RG (2017) Excessive crying. In: Textbook of Pediatric Care. American Academy of Pediatrics. 3. Lucassen PL, Assendelft WJ, van Eijk JT, Gubbels JW, Douwes AC, van Geldrop WJ (2001) Systematic review of the occurrence of infantile colic in the community. Arch Dis Child 84(5):398-403. 4. Clinical Practice Guidelines: Unsettled or crying babies. Royal Children's Hospital Melbourne. 2023. 5. Reijneveld SA, van der Wal MF, Brugman E, Hira Sing RA, Verloove-Vanhorick SP(2004) Infant crying and abuse. Lancet 364(9442):1340-1342. 6. Barr RG, Rotman A, Yaremko J, Leduc D, Francoeur TE (1992) The crying of infants with colic: a controlled empirical description. Pediatrics 90(1):14-21. 7. Savino F(2007) Focus on infantile colic. Acta Paediatr 96(9):1259-1264. 8. Sung V, Hiscock H, Tang ML et al (2014) Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomized trial. BMJ 348:g2107. 9. D'Agata AL, Baldwin N, Brownell EA, Badr MS, St John NH (2019) Infant crying: Impact of prematurity and perinatal stress. Early Hum Dev135:33-39 10. Akhnikh S, Engelberts A. C, van Sleuwen B. E, L'Hoir, M. P, & Benninga M. A (2014). The excessively crying infant: Etiology and treatment. Pediatric Annals 43(4), e69-e75. 11. Shakiba M, Momayezolashjar M, Hassani Kaboutarkhani M (2022) Investigating the effect of melatonin on infantile colic: A clinical trial. Pharmacognosy Reviews 13(S09):1142. 12. Paditz E (2024) Postnatal development of circadian rhythmicity of human pineal melatonin synthesis. Children11(10):1197. 13. Aversa S, Marseglia L, Arco A et al (2012) Efficacy and safety of melatonin in neonates. Arch Dis Child 97(Suppl 2): A464. 14. İnce T, Akman H, Çimrin D, Aydın A(2018) Role of melatonin and cortisol circadian rhythms in infantile colic. World J Pediatr14:392-398. 15. Paditz E (2024)

Individual participant data

Plan to share: Undecided — this option requires the opinion of my dean

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Mar 2026, 1 month after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2026
First posted
Mar 2, 2026
StartActual
Feb 23, 2026
Primary completionEst.
Mar 28, 2026
CompletionEst.
Apr 1, 2026
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07442162
Lead sponsor
Al-Hadba university
Responsible party
Riyadh Abdulatif Al-Obeidi (Professor and Consultant Pediatrician, Al-Hadba university) — Principal investigator
First posted
Mar 2, 2026
Start date
Feb 23, 2026
Primary completion
Mar 28, 2026 (estimated)
Completion
Apr 1, 2026 (estimated)
Last update
Mar 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion